Clinical Guides
Thalassaemia
A clinically focused clinical guide to thalassaemia diagnosis, phenotype classification, transfusion and iron-overload care, genetic counselling, and safe referral within Indian health systems.
MedNext Academy | 14 min read
Thalassaemia
A clinically focused clinical guide to thalassaemia diagnosis, phenotype classification, transfusion and iron-overload care, genetic counselling, and safe referral within Indian health systems.
Summary
Thalassaemia comprises inherited disorders in which production of an alpha- or beta-globin chain is reduced or absent. The resulting chain imbalance causes ineffective erythropoiesis, haemolysis and anaemia of widely variable severity. The most useful clinical classification is not the older label of major, intermedia or minor alone, but whether a person has transfusion-dependent thalassaemia (TDT), non-transfusion-dependent thalassaemia (NTDT), or a carrier state. These categories guide monitoring, yet they are not immutable: an NTDT phenotype can become regularly transfused because of worsening anaemia or complications, while transfusion receipt may also reflect access rather than biology.
A carrier is usually well and may have microcytosis without iron deficiency. Severe beta-thalassaemia commonly becomes apparent after fetal haemoglobin declines in infancy, with pallor, feeding difficulty, poor growth, hepatosplenomegaly or bony expansion. Haemoglobin E/beta-thalassaemia and alpha-thalassaemia produce additional phenotypes relevant in India. Diagnosis integrates full blood count and red-cell indices, blood film, iron status, haemoglobin fraction analysis by validated HPLC or capillary electrophoresis, family studies and, when needed, molecular testing. Recent transfusion can distort haemoglobin analysis and must be documented.
TDT care depends on reliable phenotype-matched red-cell transfusion, iron-overload assessment and chelation, surveillance for cardiac, liver, endocrine, bone, infectious and psychosocial complications, and timely assessment for haematopoietic cell transplantation. NTDT is not benign: iron loading, thrombosis, pulmonary hypertension, leg ulcers, extramedullary haematopoiesis and endocrine or skeletal disease may develop without regular transfusion. Screening and reproductive counselling must be voluntary, confidential and non-directive. This draft is educational, quarantined following MedNext Clinical Team review, and cannot set an individual's transfusion, chelation, transplant or prenatal-testing plan.
How Common Is It?
Thalassaemia is a major haemoglobin disorder in India, but a single national prevalence figure hides marked geographic, community and methodological variation. The National Health Mission guideline describes beta-thalassaemia and sickle cell disease as the major symptomatic haemoglobinopathies and identifies India as a setting where carrier screening, prenatal diagnosis, newborn or childhood detection, and lifelong treatment services must work together. Carrier frequencies reported from selected communities cannot be applied to every district, caste, tribe, language group or individual. Hospital series also overrepresent severe disease, whereas screening studies may use different tests and cut-offs.
Clinical burden is better understood across several populations. Carriers are far more numerous than people with severe disease. Children with TDT need repeated access to safe blood, chelation and complication surveillance; people with NTDT may remain undiagnosed until adolescence or adulthood; and couples who both carry a clinically important beta-globin variant can have an affected pregnancy. Alpha-thalassaemia and interactions such as haemoglobin E/beta-thalassaemia further complicate counting. Migration and marriage across regions mean ancestry can inform testing but must never be used as a diagnostic shortcut.
Registry completeness, laboratory standardisation and survival all influence apparent prevalence. Improved care increases the number of adults living with thalassaemia and therefore expands needs for transition, fertility, pregnancy, cardiac, endocrine and liver services. For local planning, the actionable measures are the number of people confirmed by a quality-assured laboratory, annual red-cell requirement, alloantibody burden, chelation access, MRI capacity, missed transfusions and loss to follow-up. A population estimate does not predict one person's phenotype, and a low-prevalence district still needs an urgent pathway for a severely anaemic infant or a transfusion-dependent traveller.
Risk Factors
Thalassaemia is genetic, not acquired through diet, contact or behaviour. Beta-thalassaemia is generally autosomal recessive: disease commonly results when a child inherits clinically important HBB variants from both parents, including compound states with haemoglobin E or other structural variants. Alpha-thalassaemia usually reflects deletion or dysfunction of one or more alpha-globin genes; phenotype depends on how many genes are affected and whether variants lie in cis or trans. Family history, a previous affected pregnancy, unexplained lifelong microcytosis, consanguinity and ancestry from a higher-frequency population increase the prior probability, but absence of these features does not exclude carriage.
For an affected person, risk assessment concerns complications and treatment burden. Regular transfusion creates cumulative iron exposure and risks alloimmunisation, transfusion reactions and transfusion-transmitted infection despite modern safeguards. Delayed or inadequate transfusion permits marrow expansion, splenomegaly, growth failure and extramedullary haematopoiesis. Poor chelation adherence, inaccurate dosing, limited monitoring and interrupted supply raise the risk of cardiac, hepatic and endocrine iron toxicity. NTDT can accumulate iron through increased intestinal absorption even with few transfusions; splenectomy, older age and severe ineffective erythropoiesis increase thrombotic and pulmonary vascular risk.
Record previous transfusions, antibody history, reactions, splenectomy, infections, chelators, hearing or visual symptoms, renal and hepatic function, growth, puberty, pregnancy intentions and access barriers. Family screening should follow confirmation in the index patient, with counselling before testing minors or reproductive partners. Iron supplementation is a frequent avoidable hazard: microcytosis alone is not evidence of deficiency. Conversely, a person with thalassaemia can also become iron deficient, so ferritin and the clinical context—not the diagnostic label—should determine whether iron is appropriate.
Diagnosis
History
Establish age at first pallor or jaundice, growth and developmental trajectory, feeding or exercise limitation, infections, abdominal enlargement, bone pain, fractures, gallstones and previous anaemia treatment. Obtain every transfusion date if possible, baseline and pre-transfusion haemoglobin, interval, reactions, alloantibodies, chelation exposure and adherence. Ask about neonatal screening, family microcytosis, known haemoglobin variants, affected siblings, consanguinity and previous fetal or neonatal loss without assigning blame. Document iron use, ethnicity and place of family origin as clues rather than conclusions. Adults need a transition, fertility and pregnancy history.
Examination
Assess haemodynamic stability, pallor, jaundice, hydration, growth centiles and pubertal development. Look for hepatosplenomegaly, frontal or maxillary bony expansion, skeletal deformity, leg ulcers, oedema and signs of heart failure. Evaluate infection, endocrine or liver disease when indicated. A carrier usually has no abnormal examination, and a normal examination does not exclude NTDT or a haemoglobin variant. Record spleen size consistently; rapid enlargement with acute pallor can represent sequestration or haemolysis and requires urgent assessment.
Investigations
Begin with full blood count, MCV, MCH, reticulocytes, blood film and iron studies. Thalassaemic microcytosis often has a relatively preserved red-cell count, but indices or discriminant formulae are screening clues, not confirmation. Use quality-assured HPLC or capillary electrophoresis to quantify HbA, HbA2, HbF and variants. Iron deficiency can lower HbA2, and a recent transfusion can introduce donor haemoglobin; interpret with timing and repeat when necessary. Molecular testing confirms alpha-thalassaemia, resolves complex or discordant beta phenotypes, supports family studies and is required for definitive prenatal diagnosis. In established disease, assess bilirubin, liver and renal function, ferritin trends, viral markers, red-cell phenotype or genotype and antibodies. MRI-based liver and cardiac iron assessment is preferred when available; ferritin alone cannot define organ iron. A haemoglobinopathy service should confirm diagnosis and phenotype before lifelong treatment begins.
Differential Diagnosis
The first differential for microcytic hypochromic red cells is iron deficiency. Low ferritin usually supports deficiency, while inflammation, liver disease or recent iron therapy can complicate interpretation. Iron deficiency and thalassaemia may coexist; response to iron does not erase an inherited disorder. Anaemia of inflammation, lead toxicity and sideroblastic anaemia can also be microcytic. A high red-cell count with marked microcytosis may suggest thalassaemia trait, but no index reliably replaces iron studies and haemoglobin analysis.
Other haemoglobin disorders include sickle cell disease or trait, haemoglobin E disease, haemoglobin D Punjab, unstable haemoglobins and compound heterozygous states such as HbE/beta-thalassaemia or HbS/beta-thalassaemia. Laboratory peaks must be interpreted by an experienced service because co-elution, transfusion and uncommon variants can mislead automated labels. Alpha-thalassaemia trait may have normal adult haemoglobin fractions, making molecular testing important when persistent microcytosis is unexplained. Haemoglobin H disease can produce haemolysis and characteristic inclusions but should be distinguished from beta-thalassaemia phenotypes.
In a child with anaemia, jaundice and splenomegaly, consider hereditary spherocytosis, G6PD deficiency, autoimmune haemolysis, malaria, kala-azar where epidemiologically relevant, chronic liver disease and other congenital dyserythropoietic or membrane disorders. Reticulocyte response, direct antiglobulin testing, enzyme testing timed away from acute haemolysis or transfusion, infection studies and morphology guide the pathway. Severe nutritional anaemia, malignancy and marrow failure are alternative causes of pallor and poor growth. In established thalassaemia, new anaemia may reflect alloimmune or delayed haemolytic transfusion reaction, hypersplenism, parvovirus-associated aplasia, bleeding, renal disease or a transfusion-process error. Do not attribute every deterioration to the baseline diagnosis.
Management
Management begins by defining phenotype and goals with a specialist haemoglobinopathy team. TDT requires a documented regular transfusion programme that supports normal growth, activity and suppression of ineffective erythropoiesis while limiting harm. Before the first transfusion, obtain an extended red-cell phenotype or genotype whenever feasible. Use leukocyte-reduced packed red cells selected for ABO, Rh and Kell compatibility under local blood-bank policy, screen for new antibodies before each episode, and maintain a portable record of units, reactions and antibodies. Transfusion targets and volume are individualised; abrupt changes in requirement trigger assessment for growth, adherence, alloimmunisation, haemolysis or hypersplenism.
Cumulative transfusional iron must be measured and treated. Chelation selection depends on age, iron distribution, transfusion burden, organ function, pregnancy status, prior toxicity and feasibility. Follow ferritin as a trend and use validated liver iron concentration and cardiac T2-star MRI where available. Monitor growth, puberty, glucose, thyroid, parathyroid and gonadal function, liver disease, cardiac function, bone health, infection and psychosocial wellbeing on a scheduled programme. Splenectomy is not routine because infection and thrombotic risks persist; if considered, it requires expert indication, vaccination, prophylaxis planning and lifelong education.
NTDT management is complication-driven. Some patients need intermittent or regular transfusion, chelation for iron overload, management of extramedullary haematopoiesis, thrombosis or pulmonary hypertension, and selected disease-modifying therapy. Haematopoietic cell transplantation can be curative for appropriate patients, particularly before advanced iron-related injury, but donor, conditioning and centre outcomes matter. Gene-based and newer disease-modifying treatments are evolving; foreign approval or a trial result does not establish Indian availability, licensing, affordability or long-term safety. Genetic counselling, reproductive options, school and employment support, transition to adult care, dental care, nutrition and mental health are components of comprehensive care rather than extras.
Prescribing Information
Iron chelators and disease-modifying agents require specialist prescribing with product-specific monitoring. Deferasirox can cause renal, hepatic and gastrointestinal toxicity; deferiprone can cause neutropenia or agranulocytosis; parenteral deferoxamine has infusion, auditory, visual and infection-related risks. The exact drug, formulation, dose and combination must follow current Indian product information, iron distribution, age, organ function and local protocol. Obtain baseline tests, explain sick-day and fever instructions, review interacting medicines and adjust treatment to prevent both under-chelation and toxicity from excessive exposure. A single ferritin result is not a safe dosing algorithm.
Transfusion is also a prescribed therapy. Confirm the patient, indication, target, component specification, antibody history, compatibility, volume, rate and monitoring before starting. Never add chelator directly to a blood unit. Fever, rigors, dyspnoea, hypotension, pain, dark urine or urticaria during transfusion requires immediate interruption and a formal reaction pathway, not empiric continuation. Delayed haemoglobin fall or jaundice after transfusion needs antibody and haemolysis evaluation. Maintain traceability across hospitals because an antibody may become undetectable yet remain clinically important.
Do not prescribe oral iron solely for low MCV or MCH. Confirm iron deficiency biochemically and investigate its cause. Folic acid is not a substitute for disease-specific management and should follow local indication. Luspatercept and gene-based therapies have restricted phenotype, age and regulatory criteria and require counselling about uncertain long-term outcomes. HSCT conditioning and post-transplant immunosuppression belong in accredited transplant services. Vaccination and antimicrobial prophylaxis are particularly important after splenectomy. Pregnancy may require changes in chelation and transfusion strategy; preconception multidisciplinary review is essential. This guide deliberately omits individual drug doses because safe prescribing depends on current labels and monitored patient variables.
When to Refer
Refer persistent unexplained microcytosis, abnormal haemoglobin fractions, suspected carrier couples and any child with chronic haemolytic anaemia to a clinician or laboratory experienced in haemoglobinopathies. An infant with severe anaemia, poor feeding, growth faltering, jaundice or hepatosplenomegaly needs expedited paediatric haematology assessment. Do not wait for facial or skeletal changes. Before starting a lifelong transfusion programme, confirm the diagnosis and phenotype, document pre-transfusion testing and involve a centre able to coordinate transfusion, chelation and surveillance.
Known TDT or clinically significant NTDT needs regular specialist review, not episodic transfusion alone. Escalate when transfusion requirement rises, pre-transfusion haemoglobin falls unexpectedly, antibodies appear, reactions recur, ferritin trends upward despite treatment, MRI shows organ iron, or there are cardiac, hepatic, endocrine, bone, fertility, thrombotic or pulmonary complications. Refer early for transplant assessment when a potentially eligible patient is clinically stable; late referral after irreversible organ injury narrows options. Complex variants, alpha-thalassaemia, discordant family results and prenatal diagnosis require molecular genetics and trained counselling.
Emergency referral is required for haemodynamic compromise, profound symptomatic anaemia, heart failure, severe transfusion reaction, fever in an asplenic person, acute neurological signs, suspected thrombosis, sepsis, rapidly worsening jaundice with anaemia, or acute splenic enlargement. Reproductive referral should be offered—not imposed—to a couple in whom both partners carry clinically important variants. Provide the exact laboratory reports and explain residual risk, fetal testing and locally available options non-directively. In India, confirm whether the receiving centre can supply appropriately matched blood, manage alloantibodies, perform iron MRI and provide paediatric-to-adult transition; a referral name without a workable care pathway is inadequate.
Red Flags
Acutely worsening pallor, breathlessness, tachycardia, syncope, chest pain, altered consciousness or heart failure suggests severe anaemia or a complication requiring immediate assessment. A sudden haemoglobin drop with reticulocytopenia can indicate transient aplastic crisis, often following viral illness; a fall with jaundice, dark urine and raised haemolysis markers suggests haemolysis. Rapid splenic enlargement with weakness or circulatory compromise can represent sequestration. Fever in a splenectomised patient is a medical emergency because overwhelming infection may progress before localising signs appear.
During transfusion, fever, rigors, wheeze, hypoxia, hypotension, lumbar or chest pain, haemoglobinuria, urticaria or anxiety with deterioration demands immediate cessation, identity and clerical checks, supportive treatment and blood-bank investigation. Hours to weeks later, unexpected anaemia, jaundice, fever or dark urine can signal delayed haemolytic reaction. Never assume that a previously negative antibody screen excludes a historical alloantibody. Breathlessness, oedema, arrhythmia or reduced exercise tolerance can be an early sign of cardiac iron toxicity even when serum ferritin appears moderate.
Treatment toxicity has its own red flags. Fever, sore throat or oral ulceration while taking deferiprone requires an urgent blood count and action under the prescribing protocol. Acute kidney injury, progressive proteinuria, marked transaminase rise, severe abdominal symptoms, hearing change or visual symptoms require prompt chelator review. Back pain with weakness or bladder dysfunction may reflect paraspinal extramedullary haematopoiesis and cord compression. New unilateral leg swelling, pleuritic pain, neurological deficit or severe headache raises thrombotic concern, especially in NTDT after splenectomy. Pregnancy with cardiac dysfunction, severe anaemia or iron-related organ disease requires specialist obstetric-haematology care rather than routine antenatal follow-up.
Indian Clinical Context
India's NHM framework links prevention, diagnosis and treatment through carrier screening, antenatal and newborn approaches, genetic counselling, district or day-care services and referral. Implementation is uneven. People may receive transfusions at several hospitals, purchase chelation separately and travel long distances for MRI or specialist review. A durable patient-held record should include genotype or haemoglobin analysis, red-cell phenotype or genotype, every antibody, previous reactions, transfusion specifications, iron measures, medicines and contact details. Fragmented transfusion histories create avoidable alloimmunisation and delayed-reaction risk.
Screening must protect autonomy. Community or school programmes should not label carrier status as illness, publicly disclose results, stigmatise endogamous or tribal communities, or treat marriage avoidance as the only outcome. Confirm a screening result in a quality-assured laboratory, provide understandable counselling and offer partner testing. Prenatal diagnosis requires an accurately characterised parental variant, informed consent, correct fetal-sample timing and a clear discussion of limitations and lawful locally available options. Family pressure must not replace the pregnant person's decision-making.
TIF guidance defines contemporary transfusion and iron-monitoring standards, but its assumptions about accredited blood services, molecular typing, cardiac MRI, chelator choice, transplantation and gene therapy may not be achievable everywhere in India. Likewise, the 2016 NHM clinical doses and service descriptions require reconciliation with current Indian product labels, national blood standards and local protocols. Centres should audit missed transfusions, blood availability, alloantibodies, reaction reporting, ferritin and MRI coverage, chelation interruption, growth and endocrine surveillance, transition and mortality. Equity requires navigation and decentralised monitoring without lowering safety standards. Indian comparative data on long-term outcomes, cost, regional variants and delivery models remain incomplete, so local registries should state definitions and denominators rather than promote inflated national claims.
NMC Competency Mapping
The NMC CBME curriculum supports recognition, investigation, initial stabilisation and referral, not unsupervised chronic thalassaemia management. Relevant pathology learning covers classification and investigation of anaemia, microcytic hypochromic patterns, haemolytic anaemia, the pathogenesis and blood picture of sickle cell anaemia and thalassaemia, and blood components, compatibility and transfusion reactions. Paediatrics learning includes the aetiopathogenesis, clinical features and management principles of haemolytic anaemia, thalassaemia major and sickle cell anaemia, together with history, examination for pallor or organomegaly and interpretation of common tests. Institutions should verify the exact 2024 competency wording and numbering before formal logbook use.
An undergraduate should be able to distinguish carrier microcytosis from presumptive iron deficiency, explain why a recent transfusion alters haemoglobin analysis, interpret CBC indices and a basic haemoglobin-fraction report in context, and construct a family pedigree without stigma. The learner should recognise TDT and NTDT as clinically meaningful phenotypes, describe ineffective erythropoiesis and haemolysis, identify complications of chronic anaemia, transfusion and iron overload, and state the principles of safe component therapy, chelation monitoring, vaccination after splenectomy and transplant referral.
Clinical skill ends at supervised assessment and safe escalation. Reading this guide does not certify counselling for prenatal diagnosis, interpretation of rare variants, selection of red-cell units, transfusion prescription, chelator dosing, MRI iron interpretation or transplant eligibility. Assessment should use cases: an asymptomatic adolescent with microcytosis, an infant with pallor and splenomegaly, a transfused child with fever and dark urine, and an adult with endocrine or cardiac symptoms. High-quality answers state uncertainty, request prior reports and transfusion history, avoid unnecessary iron, and refer through a functioning haemoglobinopathy pathway.
Key Exam Pearls for NEET PG
Thalassaemia results from reduced globin-chain synthesis; beta-thalassaemia causes excess unpaired alpha chains, ineffective erythropoiesis and haemolysis. Severe beta disease often presents after about six months as HbF declines. Marrow expansion can cause frontal bossing, maxillary prominence and skeletal changes; extramedullary haematopoiesis and splenomegaly reflect ineffective erythropoiesis. Modern clinical language distinguishes TDT from NTDT, while thalassaemia trait usually causes asymptomatic microcytosis. Alpha-thalassaemia severity broadly tracks the number and configuration of affected alpha genes.
A low MCV with a relatively high red-cell count suggests trait, but ferritin and haemoglobin analysis are required. Beta-thalassaemia trait typically has increased HbA2, whereas iron deficiency can lower HbA2 and obscure the pattern. Alpha-thalassaemia trait may show normal adult HPLC; molecular testing resolves suspected cases. Recent transfusion confounds haemoglobin fractions. HbE/beta-thalassaemia is an important compound state in India. Both parents carrying relevant recessive variants creates a one-in-four probability of an affected child in each pregnancy, but counselling must remain non-directive.
TDT treatment rests on regular leukocyte-reduced compatible packed cells, iron chelation and complication surveillance. Obtain extended antigen typing before transfusion when possible and remember historical alloantibodies. Serum ferritin trends are useful but do not substitute for liver iron concentration or cardiac T2-star MRI. Iron overload affects heart, liver, pituitary, pancreas, thyroid, parathyroids, gonads and bone. NTDT can develop iron overload without regular transfusion because intestinal absorption increases. HSCT can be curative but carries donor- and procedure-related risk; gene therapies remain highly selected. Never prescribe iron for microcytosis without demonstrating deficiency. Fever after splenectomy, an acute transfusion reaction and neurological signs from extramedullary masses are emergencies.
Frequently Asked Questions
Does every person with thalassaemia need regular blood transfusions for life?
No. Transfusion-dependent thalassaemia requires a regular programme, whereas many people with a carrier state need no transfusion and people with non-transfusion-dependent thalassaemia may need occasional, temporary or later regular transfusion for defined indications. Phenotype must be established by a specialist rather than inferred from the diagnostic name alone.
Can a low MCV be treated as iron deficiency without further testing?
No. Thalassaemia trait commonly causes microcytosis and unnecessary iron can delay diagnosis or add harm. Ferritin and the clinical context should establish iron deficiency, while validated haemoglobin analysis and sometimes molecular testing identify a haemoglobin disorder. Iron deficiency and thalassaemia can coexist, so results must be interpreted together.
Why are ferritin tests and MRI both used to assess iron overload?
Ferritin is accessible and useful as a trend, but inflammation, liver injury and other factors affect it, and it does not precisely show iron in individual organs. Validated MRI estimates liver iron concentration and cardiac iron, helping specialists adjust chelation while avoiding both undertreatment and chelator toxicity.
What should a person with thalassaemia carry when attending a new hospital?
Carry the confirmed diagnosis and genotype or haemoglobin-analysis report, blood group and extended phenotype or genotype, every current or historical red-cell antibody, previous reactions, recent transfusion dates, component specifications, iron-overload results, medicines and the specialist contact. These records can prevent incompatible transfusion and duplicated or unsafe decisions.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- a growing library of visual revision sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Clinical GuidesAll Clinical Guides
Browse all clinical management guides for Indian medical practice.
Test your knowledge
Attempt structured MCQs on this topic to consolidate your understanding and connect the guide to exam-focused practice.
Try MCQs on this topic